1Q26 Revenue

Our Core Strengths Create the Foundation for Diversified, Durable Growth and Dependable Performance

As a global medical technology innovator leading the way in women’s health, Hologic delivers life-changing and lifesaving detection, diagnostic and treatment solutions. Our products are rooted in The Science of Sure®, our promise to deliver world-class certainty, precision and quality to healthcare providers and their patients.

DIVISION CORE BUSINESS PRODUCTS EXPANDING PORTFOLIO

DIAGNOSTIC
SOLUTIONS

diagnostic Solutions white pie
panther
aptima ThinPrep

Panther System® • Aptima® STI Assays •

ThinPrep® Pap Test and Cytology Instruments
aptima boxes

Aptima BV and CV/TV Assays

  • Nucleic acid amplification tests.
  • Used to detect the three leading causes of vaginosis and vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis.
Breast Test

Breast Cancer Index Text™

  • Used to predict which breast cancer patients are likely to benefit from extended endocrine therapy.
  • The only test of its kind recognized by key medical societies.
  • Reimbursed by Medicare and key insurance providers.
Aptima Quant

Panther Fusion® Assays

  • Expands the molecular assay menu to run efficiently on Panther Scalable Solutions.
  • Hologic's syndromic solutions (Respiratory & Gl assays) enable testing tailored to the individual, reducing unnecessary use of resources and time.
Panther Fusion

Panther Fusion® and Panther Scalable Solutions

  • Provide access to Hologic's full menu of molecular diagnostic tests
  • Allow labs to expand existing molecular testing capabilities.
  • Increase flexibility, capacity and walkaway time.

Genius Digital Cytology

  • First CE-marked digital cytology platform to combine an artificial intelligence (Al) algorithm with advanced volumetric imaging technology.
  • Comprehensive cervical cancer screening portfolio-from sample collection to digital diagnosis..
  • Helps healthcare providers by supplying critical information needed to help guide earlier detection and better treatment decisions.

BREAST & SKELETAL
HEALTH SOLUTIONS

breast and SKELETAL white pie
3Dimensions
LOcalizer Affirm Breast System
Trident System

3Dimensions® • Affirm ® Breast Biopsy Systems •

Trident® Specimen Radiography System •

LOCalizer™ Wire-free Guidance System
Genius AI

Genius AI™

  • Supports radiologists in improving accuracy and consistency of breast cancer detection.
  • Designed to maximize effectiveness of 3D mammography.
  • Software is fully integrated on 3Dimensions systems.
Interventional Needles

Interventional Needles

  • Portfolio of tissue-acquisition needles that function with stereotactic and ultrasound systems.
  • Provide ease of use with world-class accuracy, consistency and efficiency.
Tissue Markers Tissue Markers-2

Tissue Markers

  • Serve a fast-expanding market of products for breast-conserving surgery.
  • Minimally invasive innovations that enable imaging and radiation treatment.
  • Completed Endomagnetics acquisition in July 2024, adding additional localization and tracing products to portfolio.

GYN SURGICAL
SOLUTIONS

GYN SURGICAL white pie
Novasure Image MyoSure

NovaSure® • MyoSure®
Fluent

Fluent® Pro

  • Fluid management system for hysteroscopies.
  • Provides simplified set-up and operation.
  • Advanced technology designed to increase clinical confidence.
Acessa

Sonata System

  • Transcervical fibroid ablation for treatment of symptomatic uterine fibroids.
  • Delivers a breakthrough alternative to hysterectomy and myomectomy.
  • Incisionless, transcervical delivery avoids the peritoneal cavity, allowing faster recovery times.
CollSeal

CoolSeal® Portfolio

  • Gold-standard efficacy of advanced bipolar RF vessel sealing technology.
  • Versatile applications for pediatric and gynecologic procedures.
  • Devices cut and dissect with precision in tight spaces and with minimal thermal footprint.
Omni Hysteroscope

Omni® Hysteroscopes

  • Three interchangeable sheaths to enable flexible diagnosis and treatment with a single instrument.
  • Provide a clear view of the cervical canal and uterine cavity.

Enabling healthier lives everywhere, every day.

Growing Performance, Growing Impact

Revenue Highlights 1Q26

Revenue ($M) 1Q26 Reported ∆
Vs 1Q25 		CC ∆ Vs 1Q25
Diagnostics $464.4 -1.3% -2.7%
Organic Diagnostics ex. COVID-193 $428.0 1.2% -0.3%
Molecular Diag. ex. COVID-193 $301.2 1.2% 0.0%
Breast Health $375.9 1.8% 0.8%
Organic Breast Health2 $375.8 1.9% 0.8%
GYN Surgical $180.8 8.7% 7.5%
Organic Surgical2 $171.7 3.2% 2.0%
Skeletal Health $26.7 69.0% 65.9%
Total Revenue $1,047.8 2.5% 1.3%
Organic Revenue2 $1,030.2 1.3% -0.0%
Organic ex. COVID-193 $1,002.2 2.9% 1.6%
US Revenue $773.5 2.0% -
Intl Revenue $274.3 4.0% -1.0%

Financial Overview 1Q26

Non-GAAP
In Millions ex. EPS 		1Q26 ∆ vs. 1Q25
Revenue ($M) $1,047.8 2.5%
Organic Revenue2 $1,030.2 1.3%
Organic ex. COVID-193 $1,002.2 2.9%
Gross Margin 60.1% (150 bps)
Operating Expenses $326.6 -0.7%
Operating Margin 29.0% (40 bps)
Net Margin 22.5% (90 bps)
Diluted EPS $1.04 1.0%
Adjusted EBITDA $330.4 1.3%
Hologic to be Acquired by Blackstone and TPG
  • On October 21, 2025, Hologic announced it had entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG.
  • Under the terms of the agreement, Blackstone and TPG will acquire all outstanding Hologic shares for $76 per share in cash plus a non-tradable contingent value right (CVR) to receive up to $3 per share in two payments of up to $1.50 each, for total consideration of up to $79 per share in cash.
  • The transaction is expected to close in the first half of calendar year 2026, subject to the approval of Hologic’s stockholders, the receipt of required regulatory approvals and the satisfaction of certain other customary closing conditions.
  • For more information, please see the form 8-K filed with the SEC and available on the Hologic website: Form 8-K and Agreement

Financial Results

Net Debt & Leverage Ratio1

Revenue & CC Growth Rates

Non-GAAP EPS & Growth Rates

2025 Divisional Revenue by Geography

Adjusted Operating Cash Flow4

ROIC

  1. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.
  2. Organic revenue excludes the acquired Gynesonics business, and the divested Blood and SSI businesses.
  3. Total organic revenue excluding COVID-19.
  4. Operating cash flow adjusted for one-time tax and litigation items.

© 2024 Hologic Inc. All rights reserved. Hologic and The Science of Sure are trademarks of Hologic Inc. Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries include, but are not limited to, the following: 3Dimensions, Acessa, Affirm, Aptima, Breast Cancer Index, Brevera, CoolSeal, Dimensions, Endomagnetics, Fluent, LOCalizer, MyoSure, NovaSure, Novodiag, Panther, Panther Fusion, ThinPrep. All other trademarks, registered trademarks and product names are the property of their respective owners.

Purpose-Driven Company

Through our substantial commitment to R&D innovation, we generate strong financial results, allowing us to invest in groundbreaking health initiatives for women and underserved communities.

Purpose Drive Graph
Global Health:
  • Hologic Global Women’s Health Index represents the views of 94% of the world’s women and girls aged 15 or older.
  • Global Access Initiative provides cost-effective, high-quality diagnostic testing across sub-Saharan Africa.
  • Philanthropic donations aid charitable groups focused on women’s health, STEM education and social equity.
Global Headquarters:

Marlborough, Massachusetts, US.